mTOR inhibitors have previously been studied in ER + breast cancer, but have lacked a specific biomarker predicting response, and further study of this pathway in pnSTINGlow tumors may indicate a means of selecting patients for this therapy. This evidence concerns the gene MTOR and breast cancer.